4D Molecular Therapeutics Reports Q1 2026 Results, Extends Cash Runway to H2 2028, and Completes Key Phase 3 Enrollment

summarizeSummary

4D Molecular Therapeutics reported Q1 2026 financial results, highlighted by the completion of Phase 3 enrollment for its lead wet AMD candidate, 4D-150, and an extended cash runway into the second half of 2028.

check_boxKey Events

• Q1 2026 Financial Results

  The company reported a net loss of $68.8 million for Q1 2026, compared to $48.0 million in Q1 2025, primarily due to increased R&D expenses of $65.0 million driven by Phase 3 clinical trials. Collaboration and license revenue increased to $3.0 million.

• Extended Cash Runway

  Cash, cash equivalents, and marketable securities stood at $458 million as of March 31, 2026. This is expected to fund the company's operating plan into the second half of 2028, providing significant financial stability.

• 4D-150 Phase 3 Enrollment Completed

  Enrollment for the 4D-150 4FRONT-1 wet AMD Phase 3 clinical trial was completed in February 2026, with randomization (N=523) completed in March 2026. Topline data is anticipated in H1 2027.

• Upcoming Clinical Milestones

  Key upcoming milestones include 2-year data from the PRISM wet AMD Phase 2b trial in Q3 2026, 2-year data from the SPECTRA DME trial in H2 2026, and the initiation of a global Phase 3 trial for DME in Q3 2026.

auto_awesomeAnalysis

This 8-K filing, accompanying the Q1 2026 earnings, provides a strong operational update for 4D Molecular Therapeutics. The completion of enrollment for the 4D-150 4FRONT-1 wet AMD Phase 3 trial is a significant de-risking event, moving the company closer to potential commercialization. Crucially, the company's cash position of $458 million is projected to fund operations into the second half of 2028, providing a substantial runway and alleviating near-term financing concerns, which is a critical positive for a clinical-stage biotech. While the net loss increased due to higher R&D spending, this is expected as the company advances its lead programs through late-stage clinical trials. Investors should monitor the upcoming 2-year data readouts for PRISM and SPECTRA, as well as the initiation of the global Phase 3 trial for DME, as these represent key catalysts.